In animal studies, increased expression of IL-18 was linked to exacerbation of colitis, and blocking IL-18 signalling can reduce inflammation and alleviate symptoms in models of IBD [55], highlighting the importance of IL-18 as a target for new drugs for IBD treatment. Here, IL18 is linked to colitis.